and preclinical studies revealing that IGF-1R is overexpressed in SCCHN, we have yet to find an effective way to exploit this molecular pathway. Results from Phase II head and neck cancer studies ...
Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases, announced today the presentation of ...
Lirum Therapeutics Inc. has presented data regarding their insulin-like growth factor receptor (IGF-1R) antagonist LX-101, which couples an IGF-1 variant to a cytotoxic methotrexate payload. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback